Prostatitis has remained a pathological entity that is difficult to treat.
Part of the difficultJ revolves about the putative offending pathogens. For
acute prostatitis, members of the Enterobacteriaccae, particularly Escheri
chia coli, play a central role, while intracellular pathogens such as Chlam
ydia are more frequently seen In chronic prostatitis. Consequently, a drug
needs to be able to penetrate to this specialized site in both the acute an
d chronic infection forms of the disease and also have potent activity agai
nst the most common causative pathogens, both intracellular and extracellul
ar. Levofloxacin has such an activity profile. We wished to document its ab
ility to penetrate to the site of infection. Patients undergoing prostatect
omies were administered 500 mg of levofloxacin orally every 23 h for 2 days
prior to surgery, and then on the day of surgery, 500 mg was administered
as an hour-long, constant-rate intravenous (i.v.) infusion. A set of blood
samples was obtained as guided by stochastic optimal design theory, Prostat
e biopsy times were determined by randomizing subjects into one of four gro
ups, based on the interval after the i.v. dose. All plasma and prostate dru
g concentrations were comodeled by a population modeling program, BigNPEM,
implemented on the Gray T3E Supercomputer housed at the Supercomputer Cente
r at the University of California at San Diego, Penetration was determined
as the ratio of the area under the concentration-time curve (AUC) of levofl
oxacin in the prostate to the plasma levofloxacin AUG. When calculated from
the mean population parameters, this penetration ratio was 2.96. We also p
erformed a 1,000-subject Monte Carlo simulation from the mean parameter vec
tor and covariance matrix. The mean penetration ratio here was 4.14 with a
95% confidence interval of 0.20 to 19.6. Over 70% of the population had a p
enetration ratio in excess of 1.0. Levofloxacin adequately penetrates a non
inflamed prostate and should be evaluated for the therapy of prostatitis.